Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crizanlizumab 5 mg/kg and 7.5 mg/kg versus placebo in adolescent and adult sickle cell disease
PACTR201909828957937Phase 3Recruiting
- Sponsor
- Novartis
- Start
- Aug 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial of crizanlizumab in sickle cell disease (SCD) (3 arms), sponsored by Novartis. Primary endpoints: Annualized rate of vaso-occlusive crises leading to healthcare visit: crizanlizumab 7.5 mg/kg versus placebo and Annualized rate of vaso-occlusive crises leading to healthcare visit: crizanlizumab 5.0 mg/kg versus placebo. Started Aug 2019; status: recruiting.
02
Drugs
crizanlizumab
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on PACTR201909828957937.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR201909828957937.